TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02679027

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protrude tongue maximally and upward (PTMU)
Description: The horizontal line was passing through the mid points of the distance between subnasale to stomion (upper lip height). Patients were asked to protrude tongue maximally and upward (PTMU).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protrude tongue maximally and upward (PTMU)
Description: The horizontal line was passing through the mid points of the distance between subnasale to stomion (upper lip height). Patients were asked to protrude tongue maximally and upward (PTMU).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protrude tongue maximally and downward (PTMD)
Description: The horizontal line was passing through the mid points of the distance between stomion to mentum (mandible height). Patients were asked to protrude tongue maximally and downward (PTMD).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protrude tongue maximally and downward (PTMD)
Description: The horizontal line was passing through the mid points of the distance between stomion to mentum (mandible height). Patients were asked to protrude tongue maximally and downward (PTMD).
Study: NCT03426605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label LAM-003
Description: LAM-003
Study: NCT04611321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI318
Description: IBI318 will be given fixed dose via intravenous (IV) infusion on Day 1 of each 14-day cycle until disease progression or loss of clinical benefit.
Study: NCT01423721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromihexine hydrochloride syrup
Description: syrup

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromihexine hydrochloride granules
Description: granules
Study: NCT02567773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2881078
Description: GSK2881078 hot melt solutions, ranging in concentration from 0.05 mg/g to 50 mg/g, will be prepared by weighing drug substance directly into specific quantities of the hot melt vehicle solution. Subjects will be administered GSK2881078 (dose for Cohort 1: 0.75 mg for females and 1.5 mg for males) hot melt solution within capsule orally with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2881078
Description: GSK2881078 hot melt solutions, ranging in concentration from 0.05 mg/g to 50 mg/g, will be prepared by weighing drug substance directly into specific quantities of the hot melt vehicle solution. Subjects will be administered GSK2881078 (dose for Cohort 1: 0.75 mg for females and 1.5 mg for males) hot melt solution within capsule orally with water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be administered as hot melt vehicle placebo within capsule orally with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Subjects will be administered as two capsules of itraconazole 100 mg (200 mg) orally with water.
Study: NCT03496831

Intervention type: DRUG
Intervention: Biologic Agents
Study: NCT03125200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-502
Description: Intravenous Infusion
Study: NCT03496831

Intervention type: DRUG
Intervention: Biologic Agents

Intervention type: DRUG
Intervention: Biologic Agents
Study: NCT02097082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STANZA Drug-eluting resorbable Scaffold
Study: NCT00412061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide 30 mg intramuscularly (i.m.) every 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Octreotide
Description: Octreotide 30 mg intramuscularly (i.m.) every 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 10-mg oral daily dosing regimen (two 5-mg tablets) of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: A 10-mg oral daily dosing regimen (two 5-mg tablets) of everolimus.
Study: NCT02388854

Intervention type: GENETIC
Intervention: SNPs analysis with Sanger sequencing
Description: Research of frequency of SNPs (WNT4, VEZT, FSHB and SIRT1 genes) in Sardinian women affected by endometriosis and controls

Intervention type: GENETIC
Intervention: SNPs analysis with Sanger sequencing
Description: Research of frequency of SNPs (WNT4, VEZT, FSHB and SIRT1 genes) in Sardinian women affected by endometriosis and controls
Study: NCT01714531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Goal Management Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-Based Attention-Control
Study: NCT05338489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Administered orally.
Study: NCT02740374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROTEM
Description: ROTEM coagulation assessment and guided transfusion management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard Coagulation Tests assessment and guided transfusion management
Study: NCT01853774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored navigation
Study: NCT00537693

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Renal Replacement Therapy
Description: Patients will be randomized to either arm for the first 24 hours of the study and then crossover to the second arm for the second 24 hours of the study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Renal Replacement Therapy
Description: Patients will be randomized to either arm for the first 24 hours of the study and then crossover to the second arm for the second 24 hours of the study.
Study: NCT03367650

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Blood sample and environmental survey
Description: The intervention corresponds to a 10 ml of Blood sample and an environmental survey.
Study: NCT02120053

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional protocol
Description: Teeth extractions and conventional immediate complete denture placement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone substitute material group
Description: Teeth extractions and sockets filling with bone replacement material before immediate complete denture placement
Study: NCT00636896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine plus modafinil
Description: Olanzapine 10 mg/d plus modafinil 200 mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine plus placebo
Description: Olanzapine 10 mg/d plus placebo
Study: NCT04183231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-caries varnish
Description: topical tooth varnish
Study: NCT04054024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erenumab
Description: 140 mg Erenumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Saline
Study: NCT03392571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGC-Triple regimen
Description: gemcitabine 800 mg/m2; Abraxane (nab-paclitaxel 100 mg/m2; cisplatin 25 mg/m2
Study: NCT02444403

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Police Education Program designed to align law enforcement and HIV prevention in Tijuana
Description: The 3.5-hour PEP course consists of 3 modules. Module I covers basic epidemiology, prevention and treatment of HIV, viral hepatitis and STIs, safe syringe disposal and fundamentals of addiction. Post-exposure protocols and appropriate follow-up procedures are outlined. Module II covers key provisions of Mexico's national drug policy (narcomenudeo, which defines amounts of drugs allowed for personal possession), as well as other legal provisions pertinent to HIV prevention, including the legality of syringe and condom possession. Module III covers public health-based interventions targeting PWID (SEPs, OST) and deconstructs myths typical among law enforcement (i.e., drug users do not care about their health, SEPs increase the risk of NSIs).~A sub-cohort sample will be invited to undergo pre- and post-PEP surveys with semi-annual follow-up for 2 years to assess self-reported NSIs (Aim 1), attitudinal and behavior changes (Aim 2) and mediators/moderators (Aim 3).
Study: NCT01095510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE
Study: NCT02439073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The postoperative intervention are the same in both intervention groups and consists of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.The postoperative physical exercise consists of an individually prepared supervised strength exercise - and a group-based cardiovascular exercise twice a week (60 minutes/session) on non-consecutive days for 12 weeks, a total of 24 sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: The postoperative intervention are the same in both intervention groups and consists of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.The postoperative physical exercise consists of an individually prepared supervised strength exercise - and a group-based cardiovascular exercise twice a week (60 minutes/session) on non-consecutive days for 12 weeks, a total of 24 sessions.
Study: NCT05101031

Intervention type: DEVICE
Intervention: Starling SV
Description: The Starling SV will monitor the change in hemodynamic variables (i.e. CO, SV, HR, SV) as assessed during the initial fluid resuscitation in individuals with hypotension related to infection.
Study: NCT02290730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the lower trapezius in a stretched position. The tape can be divided into one, two or three tails to cover the whole muscle from origin to insertion
Study: NCT02798250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G4 Platinum glucose sensor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G4 Platinum glucose sensor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accu Chek Combo insulin pump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accu Chek Combo insulin pump
Study: NCT00963391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ABHS use
Description: Centers assigned to the intervention group were provided with ABHS dispensers with a gel solution with ethyl alcohol at 62% as active ingredient (Purell®, GOJO Industries, Dayton, Ohio). A total of 85 dispensers were installed, one dispenser was installed in each center of size less than 14 children, and one per classroom plus an additional one for common areas in centers with more than 28 children. Proper safety measures were followed.~Standardized ABHS training workshops for staff and children in centers allocated to the intervention were carried out simultaneously with dispenser installation. Thirty minute refresher sessions about ABHS technique were provided to staff and children on a monthly basis, for a total of 8 sessions per center.
Study: NCT00732212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doppler endoscopic ultrasound probe for blood flow detection
Description: Used for blood flow detection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard endoscopic hemostasis
Description: Per current treatment guidelines for non-variceal UGI lesions - based upon stigmata of hemorrhage \& visual cues for risk stratification and completion of endoscopic treatment.
Study: NCT00869752

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-IGF-1R recombinant monoclonal antibody MK-0646
Description: MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
Study: NCT01592071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Replace reactive foods with non-reactive foods
Description: Subjects were provided with the test results and an individualized dietary plan based on replacing reactive foods with non-reactive foods as replacements per the Immuno Bloodprint results.
Study: NCT01698385

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet and exercise counseling
Description: diet and exercise counseling, setting of specific goals, follow-up of achievements, laboratory tests and measurements
Study: NCT01027715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG monitoring and treatment of EEG seizures
Description: Seizures will prompt treatment with loading doses of phenobarbital (20mg/kg), fosphenytoin (20mg/kg),and midazolam (0.05mg/kg bolus and .15mg/kg/hr infusion tapered over 48 hours)in that order for persisting seizures.
Study: NCT00485017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-4109
Description: THR-4109 maximum dose in study is 115 mg via oral capsule daily in a.m. and 115 mg via oral capsule daily in p.m. for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-4109
Description: THR-4109 maximum dose in study is 115 mg via oral capsule daily in a.m. and 115 mg via oral capsule daily in p.m. for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-4109
Description: THR-4109 maximum dose in study is 115 mg via oral capsule daily in a.m. and 115 mg via oral capsule daily in p.m. for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules daily in a.m. and in p.m. for 24 weeks
Study: NCT02899936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 drug dose - IDA
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 drug dose - DA
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA)
Study: NCT01917747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator
Description: The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed. In the second part of the study, further educational tools are given to parent(s) and discussion of additional follow up mechanisms, including community hearing services and types of interventions for pediatric hearing loss is imparted.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard scheduling and follow-up
Description: The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test, as is standard practice.
Study: NCT01217944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg ranibizumab intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg ranibizumab intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.5 mg ranibizumab intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin PDT
Description: Verteporfin (6 mg/m2) intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham Ranibizumab
Description: Empty vial to mimic the intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham Ranibizumab
Description: Empty vial to mimic the intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham Ranibizumab
Description: Empty vial to mimic the intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham verteporfin PDT
Description: Sham vPDT intravenous infusion of dextrose 5% solution followed by light application (PDT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham verteporfin PDT
Description: Sham vPDT intravenous infusion of dextrose 5% solution followed by light application (PDT).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham verteporfin PDT
Description: Sham vPDT intravenous infusion of dextrose 5% solution followed by light application (PDT).
Study: NCT04670341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chewing tapioca pearls in bubble tea drinks
Description: Saliva was collected on the first day before bubble tea consumption (pretest) and on the third day after bubble tea consumption (posttest); collection was conducted in the morning (09:00 a.m.-12.00 p.m.).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: drink tea without chewing tapioca pearls
Description: Saliva was collected on the first day before drink tea without tapioca pearl (pretest) and on the third day after tea consumption (posttest); collection was conducted in the morning (09:00 a.m.-12.00 p.m.).
Study: NCT04064593

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polygraphy
Description: The polygraphy consists of recording during sleep, respiratory flow by mean of a nasal cannula, respiratory movement by mean of a thoracic belt with inductance plethysmography, blood oxygenation and heartbeats by a fingertip transcutaneous oxymetry.~Starting and ending of the recording will be programmed based on patient interview regarding usual sleep hours.~Polygraphy data are anonymized before being sent to the Cloud and therefore to the core lab.~Polygraphic data will be scored in centralized manner.~Results of the polygraphy will be sent to the cardiology department with advice for treatment and follow-up.~If necessary, the core-lab will provide tele-counseling regarding SDB management.
Study: NCT02433340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-122
Study: NCT03218384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Description: Intravenous Ferric Carboxymaltose 750 mg mixed under sterile conditions in 100 ml of normal saline for final concentration of 7.5 mg/ml and administered via volumetric infusion pump over 15 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 100 ml of normal saline solution, and administered via volumetric infusion pump over 15 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 31P MRS/MRI
Description: Each participant will perform the same rhythmic plantar extension exercise protocol twice, for sequential acquisition of magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI) measurements. For the exercise protocol, the participant will lay supine on the scanning table with the right leg inside the volume coil. The exercise consists of repeated plantar flexion movements using resistance bands at a frequency of one repetition per second for 1-2 minutes. Data are collected continuously for 2 minutes before the exercise (baseline), during exercise, and 5 minutes after the exercise for the MRS and MRI experiments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 31P MRS/MRI
Description: Each participant will perform the same rhythmic plantar extension exercise protocol twice, for sequential acquisition of magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI) measurements. For the exercise protocol, the participant will lay supine on the scanning table with the right leg inside the volume coil. The exercise consists of repeated plantar flexion movements using resistance bands at a frequency of one repetition per second for 1-2 minutes. Data are collected continuously for 2 minutes before the exercise (baseline), during exercise, and 5 minutes after the exercise for the MRS and MRI experiments.
Study: NCT02905266

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: -Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: -Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: -Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: -Specified dose on specified days
Study: NCT00402168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: IV, IV Infusion, 5 mg/kg once every 28 days for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A
Description: Tablets, Oral, Trough of 100-250 ng/mL, 2\* daily for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tablets, Oral, Trough of 5-10 ng/mL, 2\* daily for one year